Phase IIIEnrolling💻 Remote Available

Semaglutide 2.4mg for Obesity Management in UAE Adults

🏢Novo Nordisk UAE·NCT05712398·🩺Obesity

⏱

Duration

15 months

💰

Cost

Free to Patients

🔬

Phase

Phase III

📅

Closes

Apr 2026

📋About This Trial

Evaluating the efficacy and safety of semaglutide 2.4mg weekly for weight management in UAE adult population.

📍Dubai, UAE

📍Abu Dhabi, UAE

💻Remote participation available — some or all visits can be done from home.

🩺Condition focus: Obesity

🌍Available in: UAE

💊All study medications and visits are provided at no cost to participants

🔒Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

🚪You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Check your eligibility in under 2 minutes. No commitment required — a coordinator will guide you through next steps.

Free to apply · No medical records needed to start

Trial Summary

NCT NumberNCT05712398

SponsorNovo Nordisk UAE

PhasePhase III

Duration15 months

ClosesApr 2026

ConditionObesity